» Articles » PMID: 36900366

Characteristics of Mutation in Thyroid Tumours: A Retrospective Chart Review

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2023 Mar 11
PMID 36900366
Authors
Affiliations
Soon will be listed here.
Abstract

While some studies suggest that mutations correlate with a low-risk phenotype in pediatric thyroid nodules, the relationship between the mutation and malignancy in the adult populations is abstruse. This study investigated whether mutations result in thyroid malignancy, and whether these malignancies are aggressive. This multicenter study involved 316 patients who underwent preoperative molecular testing, and subsequent lobectomy or total thyroidectomy at two quaternary care hospitals. A four-year retrospective review was performed on the 16 charts of patients that opted for surgery following a positive mutation on molecular testing results from January 2018 to December 2021. Of the total 16 patients, 37.5% ( = 6) had malignant tumours, 18.75% ( = 3) had non-invasive follicular thyroid neoplasms with papillary-like nuclear features (NIFTPs), and 43.75% ( = 7) had benign disease. Aggressive features were detected in 33.33% of the malignant tumours. Malignant tumours were found to have a statistically significant higher allele frequency (AF). The aggressive nodules were all poorly differentiated thyroid carcinomas (PDTCs) with copy number alterations (CNAs) and the highest AFs.

Citing Articles

Vitamin C in the Management of Thyroid Cancer: A Highway to New Treatment?.

Gorini F, Tonacci A Antioxidants (Basel). 2024; 13(10).

PMID: 39456495 PMC: 11505632. DOI: 10.3390/antiox13101242.


Small Multi-Gene DNA Panel Can Aid in Reducing the Surgical Resection Rate and Predicting the Malignancy Risk of Thyroid Nodules.

Oh M, Choi H, Jang J, Son H, Park S, Song M Endocrinol Metab (Seoul). 2024; 39(5):777-792.

PMID: 39397516 PMC: 11525692. DOI: 10.3803/EnM.2024.2034.


Possible link between familial susceptibility to cancer and the level of oxidative stress in thyroid cancer patients.

Javakhishvili I, Mardaleishvili K, Buleishvili M, Mantskava M, Chkhikvishvili I, Kalmakhelidze S Hered Cancer Clin Pract. 2024; 22(1):15.

PMID: 39180118 PMC: 11342469. DOI: 10.1186/s13053-024-00287-3.


A novel mutation in PTEN in anaplastic thyroid carcinoma: A case report.

Zhao Y Biomed Rep. 2024; 21(2):127.

PMID: 39006510 PMC: 11240280. DOI: 10.3892/br.2024.1815.


Biomarkers in Thyroid Cancer: Emerging Opportunities from Non-Coding RNAs and Mitochondrial Space.

Cabane P, Correa C, Bode I, Aguilar R, Elorza A Int J Mol Sci. 2024; 25(12).

PMID: 38928426 PMC: 11204084. DOI: 10.3390/ijms25126719.


References
1.
Yehia L, Ngeow J, Eng C . PTEN-opathies: from biological insights to evidence-based precision medicine. J Clin Invest. 2019; 129(2):452-464. PMC: 6355220. DOI: 10.1172/JCI121277. View

2.
Macerola E, Poma A, Vignali P, Basolo A, Ugolini C, Torregrossa L . Molecular Genetics of Follicular-Derived Thyroid Cancer. Cancers (Basel). 2021; 13(5). PMC: 7961716. DOI: 10.3390/cancers13051139. View

3.
Fusco N, Sajjadi E, Venetis K, Gaudioso G, Lopez G, Corti C . Alterations and Their Role in Cancer Management: Are We Making Headway on Precision Medicine?. Genes (Basel). 2020; 11(7). PMC: 7397204. DOI: 10.3390/genes11070719. View

4.
Milella M, Falcone I, Conciatori F, Cesta Incani U, Del Curatolo A, Inzerilli N . PTEN: Multiple Functions in Human Malignant Tumors. Front Oncol. 2015; 5:24. PMC: 4329810. DOI: 10.3389/fonc.2015.00024. View

5.
Romei C, Tacito A, Molinaro E, Piaggi P, Cappagli V, Pieruzzi L . Clinical, pathological and genetic features of anaplastic and poorly differentiated thyroid cancer: A single institute experience. Oncol Lett. 2018; 15(6):9174-9182. PMC: 5958691. DOI: 10.3892/ol.2018.8470. View